+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Glucose Modulation of Somatostatin and LHRH Release from Rat Hypothalamic Fragments in vitro

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          In the rat, hypoglycaemia inhibits growth hormone secretion, but the mechanism is unclear. To investigate this further, we have studied the effects of glucose and 2-deoxy-D-glucose on somatostatin and LHRH release from rat hypothalamic fragments incubated in vitro. Glucose (1.35–22 m M) was added to glucose-free medium and 5 and 50 m M 2-deoxy-D-glucose were added to medium containing 5.5 m M glucose. Medium somatostatin and LHRH levels were measured by RIA. Somatostatin and LHRH released diluted in parallel with synthetic somatostatin and LHRH. Sephadex gel filtration demonstrated two molecular forms of somatostatin, 70% coeluting with somatostatin-14 and 30% with somatostatin-28; LHRH coeluted with synthetic LHRH. KC1 (30–100 m M) resulted in release of somatostatin and LHRH; this was reduced in calcium-free medium. Basal and K<sup>+</sup>-stimulated somatostatin release were significantly increased by reducing glucose levels (r = -0.6, p < 0.001). Basal LHRH was not influenced by glucose. Basal and K<sup>+</sup>-induced somatostatin release were significantly increased by 2-deoxy-D-glucose (p < 0.05), while LHRH levels remained unchanged. Our results demonstrate that basal and K<sup>+</sup>-induced somatostatin release from rat hypothalamic fragments are modulated by local glucose concentrations, and this effect is specific as it is not paralleled by LHRH changes. We suggest that the reduction in growth hormone secretion during hypoglycaemia in the rat might be mediated, at least in part, via a direct effect of glucose on somatostatin release.

          Related collections

          Author and article information

          S. Karger AG
          28 March 2008
          : 39
          : 1
          : 31-38
          Departments of aEndocrinology and bChemical Endocrinology, St. Bartholomew’s Hospital, London, England
          123951 Neuroendocrinology 1984;39:31–38
          © 1984 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Original Paper


          Comment on this article